Literature DB >> 17640956

P-glycoprotein has differential effects on the disposition of statin acid and lactone forms in mdr1a/b knockout and wild-type mice.

Cuiping Chen1, Jian Lin, Teresa Smolarek, Larry Tremaine.   

Abstract

In the present study we examined the disposition of atorvastatin, lovastatin, and simvastatin in acid and lactone forms and pravastatin in acid form in multidrug-resistant gene (mdr1a/b) knockout (KO), and wild-type (WT) mice. Each statin was administered s.c. to mdr1a/b KO and WT mice at 3.0 mg/kg (n > or = 3 mice/time point). Blood, brain, and liver samples were harvested at 0, 0.5, 1.5, and 3 h postdose. Plasma and tissue concentrations of the acid and lactone (only the acid form was determined for pravastatin) were determined using a liquid chromatography-mass spectrometry method. Both lactone and acid were observed in plasma when lactones were administered, but only acids were detected when the acid forms were administered. The plasma and liver concentrations of acid or lactone were similar between the KO and WT mice. Two- to 23-fold higher concentrations were observed in liver than in plasma, suggesting potential uptake transporters involved. A significantly higher (p < 0.05) brain penetration in the KO compared with the WT mice was observed for lovastatin acid (but the brain/plasma ratio was low for both KO and WT mice) and lactone and simvastatin lactone but not for atorvastatin or pravastatin. The present results suggest that mouse P-glycoprotein does not affect the lactone-acid interconversion or liver-plasma distribution. Furthermore, P-glycoprotein plays a limited role in restricting the brain penetration of the acid forms of atorvastatin, pravastatin, simvastatin, lovastatin, and atorvastatin lactone but may limit the brain availability of the lactone forms of simvastatin and lovastatin.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17640956     DOI: 10.1124/dmd.107.015677

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  13 in total

Review 1.  Improving the prediction of the brain disposition for orally administered drugs using BDDCS.

Authors:  Fabio Broccatelli; Caroline A Larregieu; Gabriele Cruciani; Tudor I Oprea; Leslie Z Benet
Journal:  Adv Drug Deliv Rev       Date:  2011-12-21       Impact factor: 15.470

2.  Statins are ineffective at reducing neuroinflammation or prolonging survival in scrapie-infected mice.

Authors:  James A Carroll; Brent Race; Katie Phillips; James F Striebel; Bruce Chesebro
Journal:  J Gen Virol       Date:  2017-07-31       Impact factor: 3.891

Review 3.  Statins and neuroprotection: basic pharmacology needed.

Authors:  W Gibson Wood; Walter E Mΰller; Gunter P Eckert
Journal:  Mol Neurobiol       Date:  2014-01-29       Impact factor: 5.590

4.  Enteric microbiome metabolites correlate with response to simvastatin treatment.

Authors:  Rima Kaddurah-Daouk; Rebecca A Baillie; Hongjie Zhu; Zhao-Bang Zeng; Michelle M Wiest; Uyen Thao Nguyen; Katie Wojnoonski; Steven M Watkins; Miles Trupp; Ronald M Krauss
Journal:  PLoS One       Date:  2011-10-13       Impact factor: 3.240

Review 5.  The interplay between cell signalling and the mevalonate pathway in cancer.

Authors:  Peter J Mullen; Rosemary Yu; Joseph Longo; Michael C Archer; Linda Z Penn
Journal:  Nat Rev Cancer       Date:  2016-08-26       Impact factor: 60.716

6.  P-glycoprotein limits oral availability, brain penetration, and toxicity of an anionic drug, the antibiotic salinomycin.

Authors:  Jurjen S Lagas; Rolf W Sparidans; Robert A B van Waterschoot; Els Wagenaar; Jos H Beijnen; Alfred H Schinkel
Journal:  Antimicrob Agents Chemother       Date:  2008-01-14       Impact factor: 5.191

7.  Lovastatin fails to improve motor performance and survival in methyl-CpG-binding protein2-null mice.

Authors:  Claudia Villani; Giuseppina Sacchetti; Renzo Bagnati; Alice Passoni; Federica Fusco; Mirjana Carli; Roberto William Invernizzi
Journal:  Elife       Date:  2016-11-28       Impact factor: 8.140

8.  Atorvastatin downregulates co-inhibitory receptor expression by targeting Ras-activated mTOR signalling.

Authors:  Isobel Okoye; Afshin Namdar; Lai Xu; Nicole Crux; Shokrollah Elahi
Journal:  Oncotarget       Date:  2017-09-18

9.  Simvastatin-induced compartmentalisation of doxorubicin sharpens up nuclear topoisomerase II inhibition in human rhabdomyosarcoma cells.

Authors:  Martin Werner; Bihter Atil; Evelyn Sieczkowski; Peter Chiba; Martin Hohenegger
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-04-07       Impact factor: 3.000

10.  Rhabdomyolysis secondary to drug interaction between atorvastatin, omeprazole, and dexamethasone.

Authors:  Shereen Elazzazy; Saad S Eziada; Manal Zaidan
Journal:  Int Med Case Rep J       Date:  2012-09-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.